This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Feuerstein's Biotech-Stock Mailbag: Elan

Add in Tysabri uncertainty. Re-occurrence of the serious brain infection known as progressive multifocal leukoencephalopathy (PML) was expected -- warnings are in the Tysabri label -- and the two patients diagnosed with PML are alive. That's where the good news ends because it seems likely that doctors will be much more cautious about prescribing Tysabri to their multiple sclerosis patients going forward.

Sure, the diehard Elan bulls may hang on somewhat, but many of them were selling Wednesday when the bapineuzumab data came up lame. The hit from Tysabri, just a day later, is like the Wall Street version of a waterboarding. Even the very strongest hands are likely to succumb.

Consider this: The value of Fidelity Investment's massive 15% stake in Elan fell more than $900 million after the bapineuzumab data were presented. Based on Elan's after-hours swoon Thursday, the value of Fidelity's Elan investment fell $1.5 billion.

Even for Fidelity, that's a lot of money. If the mutual fund giant starts selling Elan, if it hasn't already, the stock is not going to recover anytime soon.

Let's talk valuation. Natixis Bleichroeder analyst Corey Davis, a table-pounding Elan bull, pegged Tysabri's value at $13 a share. That was before the new cases of PML popped up. He gave Elan another $3 a share in value for the base business, which includes drug delivery, and $24 a share for bapineuzumab.

Davis is not giving up on bapineuzumab, in fact, he appears to be doubling down, but just about everyone else is. So, scratch the $24 a share from his model and you're left with Elan trading at $16 a share, before this latest Tysabri scare.

The European pharma analyst at UBS puts Elan's fair value, ex-bapineuzumab, at $18 a share. That's the same guess at valuation offered to me by several Elan short-sellers Wednesday at the ICAD conference, by the way. Again, this is all before Thursday night's Tysabri shocker.
2 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ELN $0.00 0.00%
BIIB $293.21 0.31%
BMRN $96.45 0.41%
GILD $108.00 0.20%
MYGN $44.09 0.62%


Chart of I:DJI
DOW 17,798.49 -14.90 -0.08%
S&P 500 2,090.11 +1.24 0.06%
NASDAQ 5,127.5250 +11.3820 0.22%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs